In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017-Reference-Cited by-同舟云学术

In Vitro Activity of Eravacycline against Gram-Positive Bacteria Isolated in Clinical Laboratories Worldwide from 2013 to 2017

Published:2020-02-21 Issue:3 Volume:64 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Morrissey Ian¹,Hawser Stephen¹,Lob Sibylle H.²,Karlowsky James A.³,Bassetti Matteo⁴,Corey G. Ralph⁵,Olesky Melanie⁶,Newman Joseph⁶,Fyfe Corey⁶

Affiliation:

1. IHMA Europe Sàrl, Monthey, Switzerland

2. International Health Management Associates, Inc., Schaumburg, Illinois, USA

3. Department of Medical Microbiology and Infectious Diseases, Max Rady College of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada

4. Infectious Diseases Clinic, Department of Medicine, University of Udine, Udine, Italy

5. Duke University Medical Center, Durham, North Carolina, USA

6. Tetraphase Pharmaceuticals, Watertown, Massachusetts, USA

Abstract

Eravacycline is a novel, fully synthetic fluorocycline antibiotic being developed for the treatment of serious infections, including those caused by resistant Gram-positive pathogens. Here, we evaluated the in vitro activities of eravacycline and comparator antimicrobial agents against a recent global collection of frequently encountered clinical isolates of Gram-positive bacteria. The CLSI broth microdilution method was used to determine in vitro MIC data for isolates of Enterococcus spp.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/AAC.01715-19

Reference21 articles.

1. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States 2013. Centers for Disease Control and Prevention Atlanta GA. https://www.cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf.

2. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis

3. The antibiotic pipeline for multi-drug resistant gram negative bacteria: what can we expect?

4. Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent

5. Reference deleted.

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Establishment of epidemiological cut-off values for eravacycline, against Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Acinetobacter baumannii and Staphylococcus aureus;Journal of Antimicrobial Chemotherapy;2024-07-16

2. Eravacycline: a comprehensive review of in vitro activity, clinical efficacy, and real-world applications;Expert Review of Anti-infective Therapy;2024-05-08

3. Comparing novel antibiotics and carbapenems for complicated intra-abdominal infections: a systematic review and meta-analysis of randomized controlled trials;International Journal of Antimicrobial Agents;2023-08

4. Exploring the third-generation tetracycline resistance of multidrug-resistant livestock-associated methicillin-resistant Staphylococcus aureus ST9 across healthcare settings in China;Journal of Antimicrobial Chemotherapy;2023-06-08

5. In vitro activity of eravacycline and comparators against Gram-negative and Gram-positive bacterial isolates collected from patients globally between 2017 and 2020;Journal of Global Antimicrobial Resistance;2023-06